全文获取类型
收费全文 | 1735篇 |
免费 | 97篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 74篇 |
妇产科学 | 10篇 |
基础医学 | 238篇 |
口腔科学 | 16篇 |
临床医学 | 128篇 |
内科学 | 402篇 |
皮肤病学 | 36篇 |
神经病学 | 177篇 |
特种医学 | 35篇 |
外科学 | 287篇 |
综合类 | 6篇 |
一般理论 | 30篇 |
预防医学 | 172篇 |
眼科学 | 11篇 |
药学 | 47篇 |
中国医学 | 1篇 |
肿瘤学 | 164篇 |
出版年
2022年 | 10篇 |
2021年 | 21篇 |
2020年 | 17篇 |
2019年 | 21篇 |
2018年 | 30篇 |
2017年 | 34篇 |
2016年 | 30篇 |
2015年 | 39篇 |
2014年 | 46篇 |
2013年 | 58篇 |
2012年 | 93篇 |
2011年 | 103篇 |
2010年 | 70篇 |
2009年 | 65篇 |
2008年 | 127篇 |
2007年 | 109篇 |
2006年 | 115篇 |
2005年 | 110篇 |
2004年 | 96篇 |
2003年 | 102篇 |
2002年 | 103篇 |
2001年 | 21篇 |
2000年 | 10篇 |
1999年 | 17篇 |
1998年 | 24篇 |
1997年 | 34篇 |
1996年 | 26篇 |
1995年 | 28篇 |
1994年 | 20篇 |
1993年 | 15篇 |
1992年 | 10篇 |
1991年 | 26篇 |
1990年 | 11篇 |
1989年 | 13篇 |
1988年 | 12篇 |
1987年 | 5篇 |
1986年 | 9篇 |
1985年 | 10篇 |
1984年 | 7篇 |
1983年 | 14篇 |
1982年 | 17篇 |
1981年 | 14篇 |
1980年 | 5篇 |
1979年 | 11篇 |
1977年 | 10篇 |
1976年 | 10篇 |
1975年 | 10篇 |
1974年 | 8篇 |
1967年 | 6篇 |
1963年 | 4篇 |
排序方式: 共有1840条查询结果,搜索用时 15 毫秒
11.
12.
Amir?R?RazaviEmail author Hans?Gill Olle?St?l Marie?Sundquist Sten?Thorstenson Hans??hlfeldt Nosrat?Shahsavar the South-East Swedish Breast Cancer Study Group 《BMC medical informatics and decision making》2005,5(1):29
Background
A common approach in exploring register data is to find relationships between outcomes and predictors by using multiple regression analysis (MRA). If there is more than one outcome variable, the analysis must then be repeated, and the results combined in some arbitrary fashion. In contrast, Canonical Correlation Analysis (CCA) has the ability to analyze multiple outcomes at the same time. 相似文献13.
Olle Ringdén Marie Schaffer Katarina Le Blanc Ulla Persson Dan Hauzenberger Mohammad R Abedi Olle Olerup Per Ljungman Mats Remberger 《Biology of blood and marrow transplantation》2004,10(2):128-134
The aim of this study was to identify significant prognostic factors by using unrelated genomically HLA-A, -B and -DRB1-identical donors. Such data could help to choose the best donor. We studied 136 consecutive patients with hematologic malignancies and a median age of 32 years (range, 0-55 years) who received hematopoietic stem cell transplantation. Bone marrow grafts were given to 83 and peripheral blood stem cells to 53 patients. The cumulative incidence of grade II to IV acute graft-versus-host disease (GVHD) was 30% and of chronic GVHD was 54%. At 5 years, the overall transplant-related mortality (TRM) was 34%, and patient survival was 50%. In Cox multivariate analysis, 32 potential risk factors were analyzed. Monoclonal antibody OKT-3 during conditioning was correlated with grade II to IV acute GVHD, chronic GVHD, and TRM. HLA-DP mismatch was associated with poor TRM and poor survival. Cytomegalovirus-seropositive patients with a seronegative donor had a decreased leukemia-free survival. Five-year TRM was 14% with no risk factor, 38% with 1 risk factor, and 87% with 2 risk factors. The 5-year survival was 72%, 48%, and 30% with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation may be improved if an optimal donor and immunosuppression are chosen. 相似文献
14.
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. 总被引:25,自引:0,他引:25
Mesenchymal stem cells (MSCs) may be derived from adult bone marrow, fat, and several fetal tissues. In vitro, MSCs can be expanded and have the capacity to differentiate into several mesenchymal tissues, such as bone, cartilage, and fat. They escape the immune system in vitro, and this may make them candidates for cellular therapy in an allogeneic setting. They also have immunomodulatory effects, inhibit T-cell proliferation in mixed lymphocyte cultures, prolong skin allograft survival, and may decrease graft-versus-host disease (GVHD) when cotransplanted with hematopoietic stem cells. MSCs induce their immunosuppressive effect via a soluble factor. Some candidates have been suggested, and various mechanisms have also been suggested, although contradictory data exist; this may be due to differences in the cells and systems tested. A major problem has been that it has been difficult to identify and isolate MSCs after transplantation in vivo. However, MSCs seem to enhance hematopoietic engraftment in recipients of autologous and allogeneic grafts. Recently, they were found to reverse grade IV acute GVHD of the gut and liver. No tolerance was induced, however. Controlled studies are warranted. Thus, in allogeneic stem cell transplantation, MSCs may be used for hematopoiesis enhancement, as GVHD prophylaxis, and for the treatment of severe acute GVHD. They are also of potential use in the treatment of organ transplant rejection and in autoimmune inflammatory bowel disorders where immunomodulation and tissue repair are needed. 相似文献
15.
16.
17.
Abstract: The DQA1*0104 allele is known to differ from DQA1*0101 by a single nucleotide in the sequenced part of the first exon. DQA1*0104 has a guanine in the second position of the second expressed codon, whereas DQA1*0101 and all other sequenced DQA1 alleles have an adenine in that position, changing aspartic acid to glycine. The DQA1*0104 allele was originally described in African Americans with the DRB1*12, DRB3*0101, DQA1*0104, DQB1*0501, DRB1*12, DRB3*0202, DQA1*0104, DQB1*0605 or DRB1*14, DQA1*0104, DQB1*0503 haplotypes. When developing DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP), we observed that all DR10- and DR14-positive samples carried the DQA1*0104 allele, wheres all DRB1*01 -positive DNAs carried the closely related DQA1*0101 allele. In the present study, samples representing the major ethnic groups with DR-DQ haplotypes known to carry the DQA1*0104 allele or the very similar DQA1*0101 allele were investigated by Taq I RFLP analysis, PCR-SSP typing and nucleotide sequencing. The DQA1*0104 allele was found to differ from DQA1*0101 not only in the second expressed codon, but also by a productive mutation in the signal peptide. All investigated DRB1*1001 -(n = 24) and DRB1*1401 -positive (n = 25) haplotypes, defined by homozygosity or association, of Caucasian, African or Oriental origin carried the DQA1*0104 allele, whereas the DQA1*0101 allele was found on all DRB1*01 -positive (n = 32) haplotypes. These findings demonstrate that in the assignment of HLA class II alleles, polymorphism outside the second exon sometimes must be considered. The maintenance of the DQA1*0104 allele on a few distinct haplotypes indicates that the allele is old and might also be compatible with a functional difference between the DQA1*0101 and DQA1*0104 alleles. 相似文献
18.
Christopher J. Fowler Märit Eriksson Gun Thorell Olle Magnusson 《Naunyn-Schmiedeberg's archives of pharmacology》1984,327(4):279-284
Summary The in vitro inhibition by amiflamine [FLA 336(+)] and related compounds of the activity of rat monoamine oxidase (MAO)-A and-B, rat semicarbazide sensitive amine oxidase (SSAO) and human platelet poor plasma benzylamine oxidase was studied. Amiflamine was an MAO-A selective inhibitor, but also inhibits SSAO with both a reversible (competitive, K
i=200 mol/l) and a small time-dependent component which was irreversible in nature. The optical isomer FLA 336(–) was ten times less potent towards MAO-A. However, this compound was much more potent an inhibitor of SSAO (competitive, K
i=4.6 mol/l). The amiflamine metabolites FLA 788(+) and FLA 668(+) inhibited SSAO, but only at concentrations considerably higher than required for MAO-A inhibition. Ex vivo experiments indicated that there was no significant irreversible inhibition of rat heart and lung SSAO after both single and repeated administration of amiflamine at doses up to 20 times higher than required for inhibition of MAO-A within central serotoninergic neurones. 相似文献
19.
Marcus Bergström Ming Yao Malin Müller Olle Korsgren Bengt von Zur-Mühlen Torbjörn Lundgren 《Transplant international》2021,34(12):2816-2823
Allogeneic islet transplantation in type 1 diabetes requires lifelong immunosuppression to prevent graft rejection. This medication can cause adverse effects and increases the susceptibility for infections and malignancies. Adoptive therapies with regulatory T cells (Tregs) have shown promise in reducing the need for immunosuppression in human transplantation settings but have previously not been evaluated in islet transplantation. In this study, five patients with type 1 diabetes undergoing intraportal allogeneic islet transplantation were co-infused with polyclonal autologous Tregs under a standard immunosuppressive regimen. Patients underwent leaukapheresis from which Tregs were purified by magnetic-activated cell sorting (MACS) and cryopreserved until transplantation. Dose ranges of 0.14–1.27 × 106 T cells per kilo bodyweight were transplanted. No negative effects were seen related to the Treg infusion, regardless of cell dose. Only minor complications related to the immunosuppressive drugs were reported. This first-in-man study of autologous Treg infusion in allogenic pancreatic islet transplantation shows that the treatment is safe and feasible. Based on these results, future efficacy studies will be developed under the label of advanced therapeutic medical products (ATMP), using modified or expanded Tregs with the aim of minimizing the need for chronic immunosuppressive medication in islet transplantation. 相似文献
20.
James F. Markmann Michael R. Rickels Thomas L. Eggerman Nancy D. Bridges David E. Lafontant Julie Qidwai Eric Foster William R. Clarke Malek Kamoun Rodolfo Alejandro Melena D. Bellin Kathryn Chaloner Christine W. Czarniecki Julia S. Goldstein Bernhard J. Hering Lawrence G. Hunsicker Dixon B. Kaufman Olle Korsgren Christian P. Larsen Xunrong Luo Ali Naji José Oberholzer Andrew M. Posselt Camillo Ricordi Peter A. Senior A. M. James Shapiro Peter G. Stock Nicole A. Turgeon 《American journal of transplantation》2021,21(4):1477-1492